Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30438953 | 0.82 | KMT2A (0.77) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL3207873 | 0.81 | SMN1; SMN2 (0.79) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL23914117 | 0.79 | KDM4E (0.45) | KMT2AMEN1SMN1; SMN2POLBRXFP1 | |
| SCHEMBL8045987 | 0.78 | POLB (0.64) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL2926341 | 0.78 | KMT2A (0.77) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL10790461 | 0.78 | KMT2A (0.77) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL8947318 | 0.78 | KMT2A (0.67) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL14267358 | 0.78 | NPC1 (0.61) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL23387116 | 0.77 | SMPD1 (0.49) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7945842 | 0.77 | KMT2A (0.74) | KMT2AMEN1SMN1; SMN2POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239833-A1 | ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS | FUJIMOTO CHEMICALS CO., LTD., (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20210317159-A1 | ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS | FUJIMOTO CHEMICALS CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317159-A1 | ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS | ROS1, POLN, RNMT | KMT2A 1962/4885MEN1 4209/4885SMN1; SMN2 232/4885 |
| US-20240239833-A1 | ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS | ROS1, POLN, RNMT | KMT2A 1962/4885MEN1 4209/4885SMN1; SMN2 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.